In short
Clinical trials are investigating TRIGLYCERIDES MEDIUM CHAIN as part of a study in people with pulmonary arterial hypertension. The trial is looking at whether the study treatment helps improve patient status without clinical worsening. It includes adults with specific types of pulmonary arterial hypertension.
Key points
- Clinical trials investigating TRIGLYCERIDES MEDIUM CHAIN are focused on pulmonary arterial hypertension, a serious condition that affects blood flow in the lungs. The available study is a Phase 3 interventional trial with 102 planned participants. It includes patients with idiopathic, hereditary, drug- and toxin-induced, or connective tissue disease-associated pulmonary arterial hypertension. The main goal is to measure clinical improvement and no clinical worsening at week 24. The study also uses several measures such as walking distance, risk score changes, heart strain blood tests, and heart function ratios.
Trial Overview
The available study for TRIGLYCERIDES MEDIUM CHAIN is the REVIDAH study, which is described as an interventional trial in people with pulmonary arterial hypertension. It is listed as Phase 3 and has a planned enrollment of 102 participants.
The study status is Authorised, which means it has been approved to proceed in the source record. The trial is designed to assess whether the study treatment helps patients improve without getting worse over time.
Who Can Join
This trial is for patients with pulmonary arterial hypertension of specific types listed in the study record. The included groups are idiopathic, hereditary, drug- and toxin-induced, and connective tissue disease-associated pulmonary arterial hypertension.
- Idiopathic means the cause is not known.
- Hereditary means the condition runs in families.
- Drug- and toxin-induced means the condition is linked to a medicine or harmful substance.
- Associated with connective tissue disease means it happens together with another disease that affects body tissues and blood vessels.
What Is Being Measured
The main study goal is an efficacy outcome, which means the researchers want to see how well the treatment works. The main endpoint is clinical improvement and no clinical worsening.
In the study record, clinical improvement is defined by changes in at least two of these areas: walking distance, risk score, blood markers, and a heart function ratio. Clinical worsening includes hospitalisation related to pulmonary arterial hypertension, therapeutic escalation, symptom progression, lung or cardiopulmonary transplantation, atrial septostomy, or death related to pulmonary arterial hypertension.
- 6-minute walking distance (6MWD) checks how far a person can walk in 6 minutes and helps show exercise ability.
- BNP and NT-proBNP are blood tests that can reflect strain on the heart.
- TAPSE/SPAP ratio is a heart and lung blood flow measure used in the study to assess change.
- Risk score changes are used to see whether the patient moves to a lower-risk category.
Study Treatment and Study Design
The study record lists TRIGLYCERIDES MEDIUM CHAIN together with alpha-tocopherol and calcifediol as oral interventions. The brief summary also mentions a vitamin D supplement strategy with calcifediol, compared with placebo, but the source record does not provide more detail about how the listed components are assigned to participants.
Because this is an interventional study, researchers are actively testing a treatment plan rather than only observing patients. The key time point in the brief summary is week 24, when the main comparison is made.
What the Results Mean
If the study shows more clinical improvement and less clinical worsening, that would suggest the treatment approach may help people with pulmonary arterial hypertension. If the results do not show a clear difference, the study may still help researchers understand which outcome measures are most useful in this disease.
For patients, the important part of this trial is that it focuses on real-life changes such as exercise ability, blood tests, heart strain, symptoms, hospitalisation, and survival-related events. These are the kinds of outcomes that matter when studying treatment benefit in pulmonary arterial hypertension.